Psynova Neurotech

Psynova Neurotech is a company specializing in neurotechnology, focusing on developing innovative solutions to enhance mental health care and neurological research. Psynova Neurotech operates in the neurotechnology sector, aiming to create advancements in mental health solutions. The company was founded by Sarah Sadiki, who has a history of leadership in technology enterprises. The firm is headquartered in Cambridge, UK.

On March 16, 2006, Psynova raised GBP 2. 25 mn in VC funding from Porton Capital and the Cambridge Enterprise Seed Fund. The company has successfully raised a total of GBP 3. 93 mn to date, primarily through its latest funding round.

Psynova Neurotech offers a range of products aimed at improving mental health treatment and enhancing neurological research. Their services include cutting-edge neurotechnology tools that facilitate data collection and analysis for healthcare providers and researchers, promoting better outcomes in mental health care. The firm serves a diverse client base, including healthcare institutions and research organizations, primarily in the UK and Europe. For the most recent year, Psynova Neurotech reported revenues of GBP 158,424.

50. The EBITDA for the same year was GBP -1,630,785, indicating substantial investment in product development and operational expansion. Psynova Neurotech is poised to launch new products designed to further enhance its offerings in neurotechnology by early 2024. The company plans to expand its reach into emerging markets in North America and Asia by mid-2025, leveraging the recent funding of GBP 3.

93 mn to support these initiatives, particularly in product development and market entry strategies.